# Darlene Deptula-Hicks is a senior biotechnology executive with over 30 years of experience across public and private life science companies.

*biotech · news · 2026-06-10 · Business Wire*

## Key points

- Darlene Deptula-Hicks has joined Aldeyra Therapeutics’ board of directors.
- Deptula-Hicks is currently acting CFO at Normunity, a clinical-stage oncology biotech.
- Aldeyra’s pipeline includes late-stage candidates for dry eye disease and primary vitreoretinal lymphoma.
- Aldeyra’s drugs target RASP modulation, aiming to optimize multiple pathways and reduce toxicity.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyra’s board of directors (the Board). “Ms. Deptula-Hicks brings decades of experience working with both publicly traded and venture-backed biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board. “We look forward to leveraging her expertise as Aldeyra continues to progress towards potential commercialization of therapies that address an unmet medical need.” Ms. Deptula-Hicks is a senior biotechnology executive with over 30 years of experience across public and private life science companies, spanning therapeutics, diagnostics, medical devices, and emerging healthcare technologies. She has held senior executive, chief financial officer, board roles, and has extensive experience supporting companies through initial public offerings, major capital raises, strategic partnerships, and M&A transactions. Ms. Deptula-Hicks currently serves as the acting Chief Financial Officer of Normunity Inc., a clinical-stage biotech company focused on novel therapies to treat cancer. Previously, she served as Chief Financial Officer of F-star Therapeutics, Inc. Ms. Deptula-Hicks holds an M.B.A. from Rivier University and a B.S. in Accounting from Southern New Hampshire University. “I look forward to supporting Aldeyra’ s Board and partnering with the leadership team to drive sustainable long-term growth,” Ms. Deptula-Hicks stated. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

**Companies:** Aldeyra Therapeutics, Inc., Normunity Inc., F-star Therapeutics, Inc.
**Countries:** United States

[Read the full story on Business Wire](https://www.businesswire.com/news/home/20260609197950/en/Aldeyra-Therapeutics-Appoints-Darlene-Deptula-Hicks-to-Board-of-Directors)

---

Canonical: https://newsio.io/n/f4d4475e-ccc5-4859-a831-572febcd8081/darlene-deptula-hicks-is-a-senior-biotechnology-executive-with-over-30-years-of
Summarized by Newsio from Business Wire. https://newsio.io/how-it-works